Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been assigned an average rating of "Reduce" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rati